Stockreport

MeiraGTx's Parkinson's gene therapy shows promise in Phase I/II study [Yahoo! Finance]

MeiraGTx Holdings plc - Ordinary Shares  (MGTX) 
PDF The sham-controlled bridging study evaluated the company's AAV-GAD therapy over 26 weeks in 14 patients across three arms, high-dose, low-dose and a sham control. At we [Read more]